Max Chat
Share chart Zymergen Inc.
Extended chart
Simple chart
About Zymergen Inc.
Zymergen Inc. разрабатывает, проектирует и оптимизирует микробы для промышленного применения в США, Азии и Европе. У компании есть платформа, которая рассматривает геном как пространство поиска для выявления генетических изменений, которые улучшают экономику био-продуктов ее клиентов для ряда отраслей, включая химическую промышленность и материалы, сельское хозяйство и фармацевтику. Платформа Zymergen используется для открытия новых молекул, обеспечивающих уникальные свойства материалов. Компания была зарегистрирована в 2013 году и базируется в Эмеривилле, Калифорния.
Main settings
IPO date
2021-04-22
ISIN
US98985X1000
Industry
Chemicals
Sector
Materials
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 17.74 | 1 |
| P/BV | 1.07 | 9 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -73.48 | 0 |
| ROE | -113.14 | 0 |
| ROIC | -48.71 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.5876 | 10 |
| Debt/Ratio | 0.3951 | 10 |
| Debt/Equity | 0.9899 | 9 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | -2.67 | 0 |
| Yield Ebitda, % | 12.32 | 2 |
| Yield EPS, % | 49.17 | 6 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 2.43 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 2.43 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Month | 2.43 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Three month | 2.43 $ | 2.43 $ | 2.43 $ | 0 % | 0 % | 0 % |
| Half a year | 2.43 $ | 2.43 $ | 2.43 $ | 0 % | 0 % | 0 % |
| Year | 2.43 $ | 2.43 $ | 2.43 $ | 0 % | 0 % | 0 % |
| 3 years | 2.51 $ | 1.97 $ | 3.37 $ | -3.19 % | 0 % | 0 % |
| 5 years | 1.14 $ | 1.14 $ | 48.5 $ | +213.16 % | 0 % | 0 % |
| 10 years | 1.14 $ | 1.14 $ | 48.5 $ | +213.16 % | 0 % | 0 % |
| Year to date | 2.43 $ | 2.43 $ | 2.43 $ | 0 % | 0 % | 0 % |
Insider trading
| Insider | Transaction date | Date of disclosure | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
| Serber Zachariah Chief Science Officer |
02.09.2022 | 07.09.2022 | Sale | 2.21 | 7 222 | 3268 | 0 | 0 | link |
| Kim Mina Chief Legal Officer |
02.09.2022 | 07.09.2022 | Sale | 2.21 | 7 536 | 3410 | 0 | 0 | link |
| Singh Enakshi Chief Financial Officer |
02.09.2022 | 07.09.2022 | Sale | 2.21 | 8 681 | 3928 | 0 | 0 | link |
| Serber Zachariah Chief Science Officer |
11.08.2022 | 15.08.2022 | Sale | 3.91 | 21 251 | 5435 | 0 | -0.01 | link |
| Serber Zachariah Chief Science Officer |
02.06.2022 | 06.06.2022 | Sale | 1.68 | 4 724 | 2812 | 0 | 0 | link |
| Kim Mina Chief Legal Officer |
02.06.2022 | 06.06.2022 | Sale | 1.68 | 4 938 | 2939 | 0 | 0 | link |
| Kimball Aaron Chief Technology Officer |
01.02.2022 | 03.02.2022 | Sale | 5.06 | 126 500 | 25000 | 0 | -0.02 | link |
| Serber Zachariah Chief Science Officer |
31.01.2022 | 02.02.2022 | Sale | 5.03 | 27 338 | 5435 | 0 | -0.01 | link |
Main owners
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Ms. Enakshi Singh | Chief Financial Officer | 390.3k | 1978 (47 years) |
| Ms. Mina Kim | Corp. Sec. | N/A | 1974 (51 year) |
| Mike Dulin | Director of Communications | N/A | |
| Mr. Lincoln Germain | Chief Commercial Officer | N/A | |
| Mr. Subodh S. Deshmukh | Chief Devel. Officer | N/A | |
| Mr. Dmitriy Ryaboy | Chief Technology Officer | N/A | |
| Mr. Devin Scannell | Sr. VP of Drug Discovery | N/A | |
| Mr. Duane Valz J.D. | Sec. | N/A |
About company
Address: United States, EmeryVille, 5980 Horton Street - Open in google maps, Open in yandex maps
Website: http://www.zymergen.com
Website: http://www.zymergen.com
